Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track NMRA with free AI briefings, catalyst countdowns, and dilution alerts.

NMRA · Neumora Therapeutics, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$116.8M Cash on Hand
8.2mo Cash Runway
Follow NMRA by email Get an email when NMRA reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about NMRA, unsubscribe in one click. Privacy

📣 What NMRA Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Navacaprant Major Depressive Disorder Phase 3 · NCT06029439 Terminated
NMRA-323511 Alzheimer's Disease Phase 1 · NCT06546995 Completed

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

NMRA holds $116.8M in cash and short-term investments (as of Jun 30, 2026) and burns about $43M/quarter from operations, an estimated runway of 8.2 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 77 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when NMRA files for a raise →

👥 Who Owns NMRA

Insiders 23.7% Institutions (165 holders) 61.7% Public and other holders 14.6%
HolderTypeShares% of sharesAs of
Kristina Burow
Director, 10% owner · +235,026 options
Insider 33,965,419 18.00% 2026-03-30
ARCH Venture Partners X, LLC
10% owner
Insider 33,847,838 17.94% 2025-10-27
ARCH Venture Partners XII, LLC
10% owner
Includes shares also reported by ARCH Venture Partners X, LLC, counted once
Insider 33,847,838 17.94% 2025-10-27
Paul L Berns
Title: Executive Chair of the Board, Dir · +5.95M options
Insider 10,201,627 5.41% 2026-09-30
Robert A. Lenz
Head of R&D
Insider 309,092 0.16% 2025-02-18
Joshua Pinto
President & CEO, Director · +5.94M options
Insider 209,950 0.11% 2026-02-17
Daljit Singh Aurora
Title: Chief Operating and Development O · +3.16M options
Insider 48,750 0.03% 2026-08-20
Michael Lee Milligan
Title: Chief Financial Officer & Princip · +1.12M options
Insider 21,034 0.01% 2026-02-17

Share count 188,694,709 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full NMRA picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for NMRA and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.